Beam Therapeutics shares retreat after updated trial data disappoints
Beam Therapeutics shares fell 9% to $26.88 after the company shared updated trial data for BEAM-302 in alpha-1 antitrypsin deficiency.
Beam Therapeutics shares fell after the company released updated data from its trial of a treatment for alpha-1 antitrypsin deficiency. 88 on Tuesday and is roughly flat this year. The company said the data came from a Phase 1/2 trial evaluating BEAM-302 in 2 patients.